| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/00041552-200311000-00006 |
| P8608 | Fatcat ID | release_mr4e6k4g2bdkdi52w2wx24wrwq |
| P953 | full work available at URL | https://journals.lww.com/00041552-200311000-00006 |
| P698 | PubMed publication ID | 14564197 |
| P2093 | author name string | Salim Fredericks | |
| David W. Holt | |||
| P2860 | cites work | Drug Metabolism and Disposition | Q1261140 |
| Pharmacological Reviews | Q2085079 | ||
| Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans | Q28140931 | ||
| The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons | Q28141566 | ||
| cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450 | Q28609920 | ||
| Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance | Q30931256 | ||
| The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups | Q31945512 | ||
| Cytochrome P-450 3A4: regulation and role in drug metabolism | Q33636632 | ||
| Biochemical, cellular, and pharmacological aspects of the multidrug transporter | Q33636699 | ||
| P-glycoprotein and drug therapy in organ transplantation | Q33749785 | ||
| Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery | Q33904220 | ||
| The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein | Q34235311 | ||
| Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors | Q34429206 | ||
| The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics | Q34609157 | ||
| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | Q35113118 | ||
| The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump | Q35749376 | ||
| MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine | Q35803858 | ||
| Association of CYP3A4 genotype with treatment-related leukemia | Q36643196 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| Cyclosporin clinical pharmacokinetics | Q40918376 | ||
| Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil | Q43189802 | ||
| Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism | Q43531554 | ||
| Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation | Q43616677 | ||
| Human thiopurine S-methyltransferase activity in uremia and after renal transplantation | Q43647189 | ||
| Identification of functionally variant MDR1 alleles among European Americans and African Americans | Q43705904 | ||
| Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study | Q43865209 | ||
| Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. | Q43893557 | ||
| Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism | Q44028974 | ||
| C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation | Q44097588 | ||
| Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene | Q44157253 | ||
| The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. | Q44212595 | ||
| Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement | Q44255121 | ||
| Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients | Q44300400 | ||
| Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms | Q44402549 | ||
| Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. | Q44686949 | ||
| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression | Q46906576 | ||
| Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects | Q47888077 | ||
| Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. | Q53918302 | ||
| C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. | Q53970595 | ||
| First-pass metabolism of cyclosporin by the gut | Q68326644 | ||
| Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4 | Q73052606 | ||
| MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects | Q77133730 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nephrology | Q177635 |
| internal medicine | Q11180 | ||
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 607-613 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Current Opinion in Nephrology and Hypertension | Q15756282 |
| P1476 | title | Pharmacogenomics of immunosuppressive drug metabolism | |
| P478 | volume | 12 |
| Q37527189 | Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs |
| Q33849108 | Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach |
| Q34550483 | Functional interactions between P-glycoprotein and CYP3A in drug metabolism |
| Q38258677 | Pharmacogenetics and immunosuppressive drugs. |
| Q36916904 | Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation |
| Q45958498 | Prognostic effect of lymphocyte subgroup CD4+ and CD8+ cells in peripheral blood in renal transplant patients with cytomegalovirus viremia. |
| Q42837771 | Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients |
Search more.